

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Richard T. Lee, et al.
Serial No. Not Yet Assigned
Filed: August 21, 2000
For: DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR
CONDITIONS
Examiner: Not Yet Assigned
Art Unit: Not Yet Assigned

BOX PATENT APPLICATION
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Before calculating the fees, please amend the above-identified application as follows:

In the claims:

Please cancel claims 5-7, 13-14, 16, 18-19, 21-30, 33-38, 40-43, 45-47, 49, 51, 53, 58-62, 64-67, 69-70, and 73-78.

Please amend claims 8, 12, 15 and 17 as follows:

8. (Amended) An expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.

12. (Amended) An isolated polypeptide encoded by a nucleic acid molecule of claim 1, wherein the polypeptide, or fragment of the polypeptide, has cardiac cell anti-apoptotic activity.

15. (Amended) An isolated polypeptide encoded by a nucleic acid molecule of claim 1, wherein the polypeptide, or fragment of the polypeptide, is immunogenic.

17. (Amended) An isolated binding polypeptide which binds selectively a polypeptide encoded by an isolated nucleic acid molecule of claim 1.

REMARKS

Claims 5-7, 13-14, 16, 18-19, 21-30, 33-38, 40-43, 45-47, 49, 51, 53, 58-62, 64-67, 69-70 and 73-78, were cancelled solely for the purpose of reducing the cost of filing fees and without prejudice to future prosecution.

Claims 8, 12, 15 and 17 were amended to eliminate the multiple dependencies in each claim.

Respectfully submitted,

Konstantinos Andrikopoulos

Konstantinos Andrikopoulos, Reg. No. P-48,915
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Attorney's Doc. No.: P0738/7001 (ERP/KA)

August 21, 2001

x08/22/01

2025 RELEASE UNDER E.O. 14176

MARKED-UP CLAIMS

8. (Amended) An expression vector comprising the isolated nucleic acid molecule of claim 1, [2, 3, 4, 5, 6 or 7] operably linked to a promoter.

12. (Amended) An isolated polypeptide encoded by a nucleic acid molecule of claim 1, [2, 3, or 4,] wherein the polypeptide, or fragment of the polypeptide, has cardiac cell anti-apoptotic activity.

15. (Amended) An isolated polypeptide encoded by a nucleic acid molecule of claim 1, [2, 3, or 4,] wherein the polypeptide, or fragment of the polypeptide, is immunogenic.

17. (Amended) An isolated binding polypeptide which binds selectively a polypeptide encoded by an isolated nucleic acid molecule of claim 1 [2, 3, or 4].